JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2008) 197, 493-501       DOI: 10.1677/JOE-08-0071
© 2008 Society for Endocrinology
This Article
IMMEDIATE FREE ACCESS ARTICLE
Right arrow OA Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeanes, H. L
Right arrow Articles by Gray, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeanes, H. L
Right arrow Articles by Gray, G. A

Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER){alpha} agonist and unaffected by an ERβ antagonist

Helen L Jeanes, Caroline Tabor, Darcey Black1, Antwan Ederveen2 and Gillian A Gray

Centre for Cardiovascular Science, University of Edinburgh, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK1 Organon Laboratories Ltd, Department Pharmacology, Newhouse, Lanarkshire, Scotland ML1 5SH, UK2 Department Pharmacology, NV Organon, PO Box 20, 5340 BH Oss, The Netherlands

(Correspondence should be addressed to G A Gray; Email: gillian.gray{at}ed.ac.uk)

The authors declare that there are no conflicts of interest that would prejudice the impartiality of this research.

Oestrogen protects the heart from ischaemic injury. The current study aims to characterise two novel oestrogen receptor (ER) ligands, an ER{alpha} agonist ERA-45 and an ERβ antagonist ERB-88, and then use them to investigate the roles of ER{alpha} and ERβ in mediating the cardioprotection by E from ischaemia–reperfusion injury in the rat. The ER ligands were characterised by gene transactivation assay using ER-transfected Chinese hamster ovary (CHO) cells and in bioavailability studies in vivo. Female rats (n=48) were ovariectomised and implanted with 17β-oestradiol (17βE2) releasing or placebo pellets. ERA-45, ERB-88 or vehicle was administered for 5 days prior to ischaemia–reperfusion studies. Necrosis, neutrophil infiltration (myeloperoxidase activity) and oxidant stress production (electron paramagnetic resonance) from the area-at-risk were measured to assess reperfusion injury. The ER{alpha} agonist ERA-45 showed more than 35-fold selectivity for ER{alpha} compared with ERβ gene transactivation. In vitro, the ERβ antagonist ERB-88 inhibited transactivation by 17βE2 via ERβ with 46-fold selectivity relative to inhibition via ER{alpha}. In vivo, 17βE2 significantly reduced neutrophil infiltration, oxidant stress and necrosis following ischaemia and reperfusion. Cardioprotection by 17βE2 was not inhibited by ERB-88 but was completely reproduced by ERA-45. In conclusion, protection of the rat heart after ischaemia–reperfusion by 17βE2 is achieved through the reduction of cardiomyocyte death, neutrophil infiltration and oxygen-free radical availability.The results of this study indicate that these effects are primarily mediated via activation of ER{alpha}.




This article has been cited by other articles:


Home page
Exp Biol MedHome page
B. Ostadal, I. Netuka, J. Maly, J. Besik, and I. Ostadalova
Gender Differences in Cardiac Ischemic Injury and Protection--Experimental Aspects
Exp Biol Med, September 1, 2009; 234(9): 1011 - 1019.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Endocrinology.